ChromaDex and Designs for Health Partner for New Product Development on Niagen®

Rhea-AI Summary

ChromaDex (NASDAQ:CDXC) has entered into a supply agreement with Designs for Health, a U.S.-based dietary supplement manufacturer. The partnership will incorporate Niagen®, a patented form of nicotinamide riboside, into multi-ingredient products exclusively for healthcare practitioners.

This collaboration aims to enhance the distribution of Niagen® in the U.S., Canada, and Australia, leveraging Designs for Health's established network. Both companies emphasize the importance of providing science-backed health solutions to improve consumer education regarding NAD⁺.

Positive

• Supply agreement with Designs for Health enhances distribution of Niagen®.
• Niagen® is the only FDA-safety reviewed and patented form of nicotinamide riboside, which strengthens its market position.
• Collaboration targets healthcare practitioners, potentially increasing product credibility and sales.

Negative

• None.

ChromaDex announces supply agreement with Designs for Health, offering new Niagen^®-formulated products

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen^®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s extensive healthcare practitioner (HCP) network.

“We are happy to be working with a science-based company like Designs for Health to bring Niagen® to healthcare practitioners and their patients,” said Rob Fried, CEO of ChromaDex. “These practitioners play a pivotal role in educating consumers on the importance of NAD⁺ and providing science-backed health solutions.”

The Niagen® inclusive formulas will be available to healthcare practitioners through the Designs for Health network of customers throughout the United States, Canada, and Australia.

“ChromaDex has been leading the industry with NAD⁺ research and we have long admired their approach to creating high quality products as we believe in developing health products without compromise to support wellness for all. We are extremely excited to collaborate with them now and in the future,” said Jonathan Lizotte, CEO of Designs for Health.

For additional information about ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD⁺), levels of which decline with age. ChromaDex is the innovator behind NAD⁺ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen^®. Nicotinamide riboside and other NAD⁺ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to the impact the relationship will have in bringing Niagen® to healthcare practitioners and their patients and whether the practitioners will play a pivotal role in educating consumers on the importance of NAD⁺ and providing science-backed health solutions. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005167/en/

ChromaDex Media Contact:

Alex Worsham, Vice President of Global Marketing & Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

Source: ChromaDex Corporation

FAQ

What is the significance of the agreement between ChromaDex and Designs for Health?

The agreement allows ChromaDex to expand the distribution of its Niagen® products through Designs for Health's network of healthcare practitioners, enhancing market reach.

When will the new Niagen® products be available?

The new Niagen®-formulated products will be available exclusively through Designs for Health's healthcare practitioner network.

What is Niagen® and why is it important?

Niagen® is a patented form of nicotinamide riboside that is FDA-safety reviewed, crucial for promoting healthy aging and increasing NAD+ levels in the body.

In which countries will the Niagen® products be distributed?

Niagen® products will be distributed in the United States, Canada, and Australia.